Vivoryon Therapeutics N.V. (FRA:05Y)

Germany flag Germany · Delayed Price · Currency is EUR
1.612
+0.034 (2.15%)
Last updated: Dec 1, 2025, 9:08 AM CET
-15.25%
Market Cap47.68M
Revenue (ttm)n/a
Net Income (ttm)-12.48M
Shares Outn/a
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume122
Open1.612
Previous Close1.578
Day's Range1.612 - 1.612
52-Week Range1.404 - 2.685
Betan/a
RSI41.80
Earnings DateDec 4, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 14
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 05Y
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.